CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Biomarker
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
    Technologies and Software
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

Deep Dive - Immunotherapy Development

What Matters in Personalized Immunotherapy Development

By

Life Sciences Review | Tuesday, November 10, 2026

Cancer poses a challenge for immunotherapy because cancer cells within the same tumor can express different antigens. Some treatments focus on a specific antigen or immune checkpoint, which may limit the range of cancer cells they can address. Developing an approach that accounts for this variation requires a broader understanding of the tumor and how the immune system can be trained to recognize it. The choice of biological material used in treatment is therefore an important part of evaluating personalized immunotherapy.


A treatment developed for an individual patient brings additional challenges. Therapies that use a patient’s own tumor material and immune cells depend on obtaining a viable tissue sample and collecting the necessary cells. Each treatment must then be manufactured separately, with careful handling throughout the process. This makes production more complicated than manufacturing a standardized product in large batches.


The process needs to account for how specimens are received, transferred and prepared, as well as the time required to manufacture and release each treatment. Patient-specific material must remain properly identified and handled at every stage. The provider also needs a clear approach when an adequate tumor sample cannot be obtained, since this can affect whether treatment can proceed.


Determining who may be suitable for treatment is equally important. Not every patient will have the required tumor material available, and the timing of treatment may influence whether the process is appropriate. Medical teams need to review each case before manufacturing begins. Communication between clinicians and laboratory staff is also essential when treatment schedules change or other therapies affect eligibility. Even a carefully manufactured cell product depends on appropriate patient selection and treatment timing.


“Immunocine develops individualized dendritic cell therapies using a patient’s own tumor material and immune cells, with the aim of exposing the immune system to a broad range of tumor targets.”


Monitoring the immune response is another important part of development. Routine blood counts alone cannot show how different immune-cell populations are responding to treatment. More detailed testing can help identify whether immune cells are becoming activated, suppressed or exhausted, and whether memory responses are developing.


These measurements provide information about the biological response the treatment is intended to produce. They also give clinicians additional evidence to consider alongside imaging and other medical findings. The value lies in understanding how the immune system changes during treatment, rather than simply collecting more laboratory results.


Quality control presents its own demands when every treatment is manufactured for a single patient. Each product needs testing to confirm that it meets the required standards before use. Sterility and cell viability are particularly important, along with records showing that the manufacturing process was followed correctly for that individual treatment.


Independent laboratory verification adds another level of assurance. When a manufacturer performs its own testing, external checks can provide additional confirmation of product quality. Clear documentation, release procedures and traceable records help ensure that these safeguards are part of routine manufacturing rather than steps introduced only when concerns arise.


Immunocine develops individualized dendritic cell therapies using a patient's own tumor material and immune cells, with the aim of exposing the immune system to a broad range of tumor targets. Its process involves loading the patient's dendritic cells with total tumor mRNA and proteins before returning the cells near functional draining lymph nodes.


Treatment begins with a review of the patient's medical records to assess candidacy. Manufacturing depends on obtaining a viable tumor sample and collecting the patient's own immune cells. This makes the process specific to each individual rather than relying on a standardized treatment product.


Immunocine also monitors immune-system changes throughout treatment using flow cytometry. This allows its team to examine changes in immune-cell populations and assess the biological response over time.


The company combines internal analysis of manufactured cell products with independent laboratory verification. Release testing and certificates of analysis are used before a vaccine is administered, providing documented checks on the finished product.


For those evaluating personalized immunotherapy development, Immunocine brings together broad tumor-targeting methods, individualized cell manufacturing, immune monitoring and documented quality controls. Its approach addresses both the biological complexity of cancer and the practical requirements of preparing and evaluating a treatment made for an individual patient.


Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/deep-dive/what-matters-in-personalized-immunotherapy-development-nwid-3904.html